The investment-grade notes offering consists of six tranches

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered debt offering by Merck & Co., Inc. of $6 billion aggregate principal amount of notes. The notes were offered in six tranches, maturing in 2028, 2030, 2033, 2044, 2053 and 2063.

Merck & Co., Inc. is a global healthcare company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its operations are principally managed on a product basis and include two operating segments, pharmaceutical and animal health.

The Davis Polk capital markets team included partner Byron B. Rooney, counsel Judah Bareli and associate Logan Crossley. The tax team included partner Michael Farber and associate Justin Corvino. All members of the Davis Polk team are based in the New York office.